

**Amendments to the Specification:**

Please add the following paragraph prior to the first paragraph of the specification:

--CROSS-RELATED AND PRIORITY APPLICATIONS

This application is a divisional application of U.S. Application No. 09/486,550, filed February 29, 2000, which claims benefit of priority under 35 U.S.C. § 371 of PCT/US98/17830, filed August 28, 1998, which claims benefit of priority of U.S. Application No. 60/056,272, filed August 29, 1997. These priority documents are hereby incorporated by reference in their entirety.--

Please add the following Abstract after the last paragraph of the paragraph and subsequent to the claims:

-- ABSTRACT

This invention provides compounds and methods for treating, with said compound, a mycobacterial infection by administering to an animal a pharmaceutical composition containing a compound having the formula  $R-SO_n-Z-CO-Y$ , where R is an alkyl groups having 6-20 carbon atoms, unsaturated hydrocarbon groups having 6-20 carbon atoms, or alkyl groups having 6-20 carbon atoms interrupted by at least one aromatic ring; Z is  $-CH_2-$ ,  $-CH_2CH_2-$ ,  $-NH-NH-$ ,  $-O-$ ,  $-NH-$ ,  $-O-NH-$ ,  $-CH_2-NH-$ ,  $-CH_2-O-$ ,  $-NH-O-$ ,  $-NH-CH_2-$ ,  $-O-CH_2-$ , and  $-CH=CH-$ ; Y is  $-NH_2$ ,  $-O-CH_2-C_6H_5$ ,  $-CO-CO-O-CH_3$ , and  $-O-CH_3$ ; and n is 1 or 2. It has been discovered that these compounds treat microbially-based infections caused by corynebacteria, nocardiae, rhodococcus, and mycobacteria. These compounds may be used to treat mycobacterial cells, such as *Mycobacteria tuberculosis*, drug resistant *M. tuberculosis*, *M. avium intracellulare*, *M. leprae*, *M. paratuberculosis*, and pathogenic *Mycobacteria sp.*--